Leith Wheeler Investment Counsel Ltd. Acquires Shares of 81,408 Icon Plc $ICLR

Leith Wheeler Investment Counsel Ltd. acquired a new position in shares of Icon Plc (NASDAQ:ICLR) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 81,408 shares of the medical research company’s stock, valued at approximately $9,009,000.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. WINTON GROUP Ltd acquired a new stake in shares of Icon in the second quarter valued at about $254,000. Daiwa Securities Group Inc. lifted its position in Icon by 19.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock worth $4,094,000 after acquiring an additional 4,546 shares in the last quarter. Frontier Capital Management Co. LLC boosted its holdings in Icon by 97.6% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock worth $10,379,000 after acquiring an additional 35,253 shares during the period. Peapack Gladstone Financial Corp acquired a new stake in Icon in the second quarter valued at approximately $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Icon by 58.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 289 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ICLR. Jefferies Financial Group reissued a “buy” rating and set a $165.00 target price on shares of Icon in a research report on Friday, May 29th. UBS Group set a $160.00 price target on shares of Icon in a report on Wednesday, June 24th. Citigroup lifted their price target on shares of Icon from $140.00 to $165.00 and gave the stock a “neutral” rating in a research note on Thursday, June 25th. DA Davidson set a $164.00 price objective on shares of Icon in a research report on Monday, June 1st. Finally, Barclays raised their target price on Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research note on Thursday, June 25th. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $173.19.

Icon Stock Down 2.2%

ICLR stock opened at $166.18 on Tuesday. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 0.31. The firm has a 50 day simple moving average of $147.16 and a 200-day simple moving average of $136.57. The company has a market capitalization of $12.72 billion, a P/E ratio of 29.57, a PEG ratio of 8.34 and a beta of 1.22. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.